Share Price and Basic Stock Data
Last Updated: December 13, 2025, 9:04 am
| PEG Ratio | 11.18 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Syngene International Ltd, a prominent player in the biopharmaceutical sector, has shown a steady revenue trajectory over recent years. For the financial year ending March 2025, the company reported sales of ₹3,642 Cr, reflecting a solid growth from ₹3,193 Cr the previous year. This upward trend is indicative of its robust operational capabilities and the growing demand for its contract research and manufacturing services. The trailing twelve months (TTM) revenue stands at ₹3,727 Cr, suggesting that the company is maintaining its momentum. However, a closer look at quarterly sales reveals fluctuations; for instance, sales dipped to ₹790 Cr in June 2024 from ₹994 Cr in March 2023. Such variations may raise questions about the predictability of revenue streams, but overall, the long-term growth pattern appears promising.
Profitability and Efficiency Metrics
Profitability remains a strong suit for Syngene, with a net profit of ₹496 Cr reported for FY 2025, slightly down from ₹510 Cr in FY 2024. The operating profit margin (OPM) was reported at 29% for FY 2025, reflecting a consistent efficiency in managing operational costs. Notably, the interest coverage ratio (ICR) stands at an impressive 20.97x, which indicates that the company generates ample earnings to cover its interest obligations. This positions Syngene as a financially stable entity, capable of weathering economic fluctuations. However, the return on equity (ROE) is reported at 10.49%, which, while decent, may not excite investors when compared to higher benchmarks in the industry. The cash conversion cycle (CCC) of -23 days indicates efficient management of working capital, although it’s essential to monitor how fluctuations in inventory days, which stood at 60 for FY 2025, might affect future profitability.
Balance Sheet Strength and Financial Ratios
Syngene’s balance sheet reveals a measured approach to leveraging, with total borrowings at ₹582 Cr, a figure that remains manageable given the company’s strong equity base. The total reserves have increased to ₹4,332 Cr, reflecting a healthy retention of profits that can be reinvested into the business. The price-to-book value (P/BV) ratio is currently at 6.18x, suggesting that the market has high expectations for future growth, although it also implies that the stock may be priced at a premium. The current ratio of 1.64 indicates a comfortable liquidity position, which is critical in the capital-intensive biopharma sector. However, with a relatively high P/E ratio of 55.1, investors might question whether the current valuations are justified given the mixed performance on profitability metrics.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Syngene indicates a balanced mix of ownership, with promoters holding 52.68%, foreign institutional investors (FIIs) at 16.31%, and domestic institutional investors (DIIs) at 24.62%. The recent decline in promoter shareholding from 64.86% in December 2022 to the current level could be seen as a sign of dilution of control, which may concern some investors. On the flip side, the increase in DII holdings from 7.03% to 24.62% during the same period might reflect growing institutional confidence in the company’s fundamentals. The total number of shareholders has also increased to 1,36,061, suggesting a broadening base of retail interest. This mix of institutional and retail investment could provide a stabilizing effect amidst market volatility.
Outlook, Risks, and Final Insight
Looking ahead, Syngene’s growth prospects appear to hinge on its ability to navigate the competitive landscape of the biopharmaceutical sector. While the company has a solid operational foundation, risks such as fluctuating demand for its services, regulatory challenges, and potential pricing pressures could impact performance. The recent revenue fluctuations might suggest that the company should work towards stabilizing its sales growth. Investors should also consider the high P/E ratio in relation to its ROE, which could imply that future growth needs to be substantial to justify current valuations. Overall, Syngene stands as a robust player in its field, but potential investors should weigh the strengths against the evolving risks in the market landscape before making decisions.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Mipco Seamless Rings (Gujarat) Ltd | 9.34 Cr. | 26.0 | 37.4/22.0 | 3.71 | 0.00 % | % | % | 10.0 | |
| MPIL Corporation Ltd | 26.2 Cr. | 460 | 787/362 | 242 | 0.10 % | 12.8 % | 15.5 % | 10.0 | |
| FGP Ltd | 12.0 Cr. | 10.1 | 13.7/7.32 | 3.09 | 0.00 % | 0.00 % | 0.89 % | 10.0 | |
| Logica Infoway Ltd | 409 Cr. | 230 | 272/173 | 29.8 | 53.0 | 0.00 % | 14.3 % | 14.1 % | 10.0 |
| CRP Risk Management Ltd | 10.8 Cr. | 6.18 | 10.6/5.61 | 34.6 | 0.00 % | 0.00 % | 0.00 % | 10.0 | |
| Industry Average | 8,454.25 Cr | 284.30 | 42.75 | 104.34 | 0.03% | 48.42% | 7.44% | 9.00 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 644 | 768 | 786 | 994 | 808 | 910 | 854 | 917 | 790 | 891 | 944 | 1,018 | 874 |
| Expenses | 472 | 552 | 555 | 680 | 596 | 656 | 622 | 600 | 620 | 646 | 660 | 674 | 668 |
| Operating Profit | 173 | 216 | 231 | 314 | 212 | 254 | 232 | 317 | 170 | 245 | 284 | 344 | 206 |
| OPM % | 27% | 28% | 29% | 32% | 26% | 28% | 27% | 35% | 22% | 27% | 30% | 34% | 24% |
| Other Income | 16 | 15 | 17 | 23 | 24 | 14 | 26 | 16 | 50 | 16 | 18 | 19 | 18 |
| Interest | 9 | 12 | 14 | 10 | 10 | 13 | 11 | 13 | 12 | 13 | 12 | 16 | 12 |
| Depreciation | 86 | 90 | 95 | 96 | 102 | 105 | 108 | 111 | 107 | 111 | 109 | 106 | 111 |
| Profit before tax | 93 | 130 | 140 | 231 | 123 | 151 | 138 | 209 | 101 | 137 | 181 | 240 | 101 |
| Tax % | 20% | 22% | 22% | 23% | 24% | 23% | 19% | 10% | 25% | 23% | 27% | 24% | 14% |
| Net Profit | 74 | 102 | 110 | 179 | 93 | 116 | 112 | 189 | 76 | 106 | 131 | 183 | 87 |
| EPS in Rs | 1.84 | 2.54 | 2.73 | 4.45 | 2.32 | 2.90 | 2.77 | 4.69 | 1.88 | 2.64 | 3.26 | 4.55 | 2.15 |
Last Updated: August 1, 2025, 10:45 am
Below is a detailed analysis of the quarterly data for Syngene International Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 874.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,018.00 Cr. (Mar 2025) to 874.00 Cr., marking a decrease of 144.00 Cr..
- For Expenses, as of Jun 2025, the value is 668.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 674.00 Cr. (Mar 2025) to 668.00 Cr., marking a decrease of 6.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 206.00 Cr.. The value appears to be declining and may need further review. It has decreased from 344.00 Cr. (Mar 2025) to 206.00 Cr., marking a decrease of 138.00 Cr..
- For OPM %, as of Jun 2025, the value is 24.00%. The value appears to be declining and may need further review. It has decreased from 34.00% (Mar 2025) to 24.00%, marking a decrease of 10.00%.
- For Other Income, as of Jun 2025, the value is 18.00 Cr.. The value appears to be declining and may need further review. It has decreased from 19.00 Cr. (Mar 2025) to 18.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 12.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 16.00 Cr. (Mar 2025) to 12.00 Cr., marking a decrease of 4.00 Cr..
- For Depreciation, as of Jun 2025, the value is 111.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 106.00 Cr. (Mar 2025) to 111.00 Cr., marking an increase of 5.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 101.00 Cr.. The value appears to be declining and may need further review. It has decreased from 240.00 Cr. (Mar 2025) to 101.00 Cr., marking a decrease of 139.00 Cr..
- For Tax %, as of Jun 2025, the value is 14.00%. The value appears to be improving (decreasing) as expected. It has decreased from 24.00% (Mar 2025) to 14.00%, marking a decrease of 10.00%.
- For Net Profit, as of Jun 2025, the value is 87.00 Cr.. The value appears to be declining and may need further review. It has decreased from 183.00 Cr. (Mar 2025) to 87.00 Cr., marking a decrease of 96.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 2.15. The value appears to be declining and may need further review. It has decreased from 4.55 (Mar 2025) to 2.15, marking a decrease of 2.40.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:20 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,423 | 1,826 | 2,012 | 2,184 | 2,604 | 3,193 | 3,489 | 3,642 | 3,727 |
| Expenses | 949 | 1,289 | 1,394 | 1,507 | 1,806 | 2,251 | 2,472 | 2,598 | 2,649 |
| Operating Profit | 474 | 537 | 618 | 678 | 798 | 942 | 1,017 | 1,045 | 1,078 |
| OPM % | 33% | 29% | 31% | 31% | 31% | 30% | 29% | 29% | 29% |
| Other Income | 53 | 75 | 153 | 94 | 20 | 63 | 77 | 101 | 71 |
| Interest | 23 | 32 | 35 | 28 | 24 | 45 | 47 | 53 | 53 |
| Depreciation | 131 | 164 | 219 | 274 | 310 | 366 | 426 | 433 | 437 |
| Profit before tax | 372 | 415 | 517 | 469 | 484 | 594 | 621 | 660 | 660 |
| Tax % | 18% | 20% | 20% | 14% | 18% | 22% | 18% | 25% | |
| Net Profit | 305 | 332 | 412 | 405 | 396 | 464 | 510 | 496 | 507 |
| EPS in Rs | 7.64 | 8.29 | 10.30 | 10.12 | 9.88 | 11.57 | 12.69 | 12.33 | 12.60 |
| Dividend Payout % | 7% | 3% | 0% | 0% | 10% | 11% | 10% | 10% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 8.85% | 24.10% | -1.70% | -2.22% | 17.17% | 9.91% | -2.75% |
| Change in YoY Net Profit Growth (%) | 0.00% | 15.24% | -25.80% | -0.52% | 19.39% | -7.26% | -12.66% |
Syngene International Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 13% |
| 3 Years: | 12% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 4% |
| TTM: | 6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 7% |
| 3 Years: | 5% |
| 1 Year: | -28% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 13% |
| 3 Years: | 12% |
| Last Year: | 11% |
Last Updated: September 5, 2025, 1:41 pm
Balance Sheet
Last Updated: December 4, 2025, 2:04 am
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 200 | 200 | 400 | 400 | 401 | 401 | 402 | 402 | 403 |
| Reserves | 1,520 | 1,768 | 1,776 | 2,421 | 2,897 | 3,217 | 3,856 | 4,324 | 4,332 |
| Borrowings | 787 | 813 | 773 | 893 | 1,022 | 815 | 555 | 578 | 582 |
| Other Liabilities | 681 | 922 | 1,214 | 1,169 | 1,245 | 1,398 | 1,339 | 1,491 | 1,226 |
| Total Liabilities | 3,189 | 3,704 | 4,163 | 4,883 | 5,564 | 5,831 | 6,152 | 6,796 | 6,542 |
| Fixed Assets | 1,030 | 1,377 | 2,020 | 2,201 | 2,393 | 2,667 | 2,850 | 2,802 | 3,049 |
| CWIP | 155 | 274 | 234 | 237 | 346 | 177 | 838 | 1,266 | 989 |
| Investments | 158 | 716 | 776 | 702 | 1,034 | 918 | 548 | 647 | 547 |
| Other Assets | 1,846 | 1,337 | 1,133 | 1,743 | 1,790 | 2,069 | 1,916 | 2,081 | 1,957 |
| Total Assets | 3,189 | 3,704 | 4,163 | 4,883 | 5,564 | 5,831 | 6,152 | 6,796 | 6,542 |
Below is a detailed analysis of the balance sheet data for Syngene International Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 403.00 Cr.. The value appears strong and on an upward trend. It has increased from 402.00 Cr. (Mar 2025) to 403.00 Cr., marking an increase of 1.00 Cr..
- For Reserves, as of Sep 2025, the value is 4,332.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,324.00 Cr. (Mar 2025) to 4,332.00 Cr., marking an increase of 8.00 Cr..
- For Borrowings, as of Sep 2025, the value is 582.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 578.00 Cr. (Mar 2025) to 582.00 Cr., marking an increase of 4.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,226.00 Cr.. The value appears to be improving (decreasing). It has decreased from 1,491.00 Cr. (Mar 2025) to 1,226.00 Cr., marking a decrease of 265.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 6,542.00 Cr.. The value appears to be improving (decreasing). It has decreased from 6,796.00 Cr. (Mar 2025) to 6,542.00 Cr., marking a decrease of 254.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 3,049.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,802.00 Cr. (Mar 2025) to 3,049.00 Cr., marking an increase of 247.00 Cr..
- For CWIP, as of Sep 2025, the value is 989.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,266.00 Cr. (Mar 2025) to 989.00 Cr., marking a decrease of 277.00 Cr..
- For Investments, as of Sep 2025, the value is 547.00 Cr.. The value appears to be declining and may need further review. It has decreased from 647.00 Cr. (Mar 2025) to 547.00 Cr., marking a decrease of 100.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,957.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,081.00 Cr. (Mar 2025) to 1,957.00 Cr., marking a decrease of 124.00 Cr..
- For Total Assets, as of Sep 2025, the value is 6,542.00 Cr.. The value appears to be declining and may need further review. It has decreased from 6,796.00 Cr. (Mar 2025) to 6,542.00 Cr., marking a decrease of 254.00 Cr..
Notably, the Reserves (4,332.00 Cr.) exceed the Borrowings (582.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -313.00 | -276.00 | -155.00 | -215.00 | 797.00 | 127.00 | -554.00 | -577.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 68 | 68 | 72 | 79 | 71 | 61 | 46 | 53 |
| Inventory Days | 82 | 30 | 18 | 41 | 87 | 141 | 94 | 60 |
| Days Payable | 195 | 154 | 156 | 167 | 113 | 109 | 100 | 136 |
| Cash Conversion Cycle | -44 | -56 | -66 | -47 | 45 | 92 | 40 | -23 |
| Working Capital Days | -48 | -103 | -172 | -66 | -43 | -14 | -27 | -51 |
| ROCE % | 17% | 17% | 14% | 13% | 15% | 15% | 14% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Mirae Asset Focused Fund | 4,137,512 | 3.37 | 268.98 | 3,831,558 | 2025-12-08 06:31:04 | 7.99% |
| Nippon India Small Cap Fund | 4,079,850 | 0.38 | 265.23 | N/A | N/A | N/A |
| Mirae Asset Large & Midcap Fund | 3,936,400 | 0.6 | 255.91 | N/A | N/A | N/A |
| ICICI Prudential ELSS Tax Saver Fund | 3,770,138 | 1.65 | 245.1 | 3,400,267 | 2025-12-08 06:31:04 | 10.88% |
| DSP ELSS Tax Saver Fund | 3,737,983 | 1.41 | 243.01 | N/A | N/A | N/A |
| Nippon India Focused Fund | 3,708,177 | 2.77 | 241.07 | N/A | N/A | N/A |
| Mirae Asset ELSS Tax Saver Fund | 3,387,681 | 0.81 | 220.23 | N/A | N/A | N/A |
| DSP Large & Mid Cap Fund | 3,369,970 | 1.33 | 219.08 | N/A | N/A | N/A |
| ICICI Prudential Multicap Fund | 3,273,806 | 1.32 | 212.83 | 1,811,685 | 2025-12-08 06:31:04 | 80.71% |
| Mirae Asset Midcap Fund | 3,001,089 | 1.08 | 195.1 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 12.35 | 12.71 | 11.59 | 9.94 | 10.18 |
| Diluted EPS (Rs.) | 12.34 | 12.69 | 11.51 | 9.82 | 10.11 |
| Cash EPS (Rs.) | 23.07 | 23.28 | 20.70 | 17.60 | 16.98 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 117.44 | 105.92 | 90.13 | 82.28 | 70.53 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 117.44 | 105.92 | 90.13 | 82.28 | 70.53 |
| Revenue From Operations / Share (Rs.) | 90.49 | 86.78 | 79.54 | 64.97 | 54.61 |
| PBDIT / Share (Rs.) | 27.67 | 27.49 | 25.04 | 21.18 | 18.41 |
| PBIT / Share (Rs.) | 16.92 | 16.89 | 15.91 | 13.45 | 11.55 |
| PBT / Share (Rs.) | 16.40 | 15.44 | 14.79 | 12.09 | 11.73 |
| Net Profit / Share (Rs.) | 12.33 | 12.69 | 11.57 | 9.88 | 10.12 |
| NP After MI And SOA / Share (Rs.) | 12.33 | 12.69 | 11.57 | 9.88 | 10.12 |
| PBDIT Margin (%) | 30.57 | 31.67 | 31.48 | 32.59 | 33.71 |
| PBIT Margin (%) | 18.69 | 19.46 | 20.00 | 20.70 | 21.14 |
| PBT Margin (%) | 18.11 | 17.79 | 18.59 | 18.60 | 21.48 |
| Net Profit Margin (%) | 13.62 | 14.61 | 14.54 | 15.19 | 18.53 |
| NP After MI And SOA Margin (%) | 13.62 | 14.61 | 14.54 | 15.19 | 18.53 |
| Return on Networth / Equity (%) | 10.49 | 11.97 | 12.83 | 12.00 | 14.35 |
| Return on Capital Employeed (%) | 12.61 | 13.56 | 13.75 | 12.43 | 12.31 |
| Return On Assets (%) | 7.30 | 8.29 | 7.96 | 7.11 | 8.29 |
| Long Term Debt / Equity (X) | 0.00 | 0.02 | 0.13 | 0.16 | 0.18 |
| Total Debt / Equity (X) | 0.02 | 0.03 | 0.15 | 0.23 | 0.27 |
| Asset Turnover Ratio (%) | 0.56 | 0.58 | 0.55 | 0.49 | 0.48 |
| Current Ratio (X) | 1.64 | 1.71 | 2.04 | 1.79 | 1.59 |
| Quick Ratio (X) | 1.53 | 1.50 | 1.76 | 1.65 | 1.54 |
| Inventory Turnover Ratio (X) | 4.70 | 3.06 | 3.52 | 6.45 | 13.01 |
| Dividend Payout Ratio (NP) (%) | 10.13 | 9.86 | 8.63 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 5.41 | 5.37 | 4.82 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 89.87 | 90.14 | 91.37 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 94.59 | 94.63 | 95.18 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 20.97 | 23.41 | 22.24 | 35.22 | 26.58 |
| Interest Coverage Ratio (Post Tax) (X) | 9.74 | 12.04 | 11.27 | 18.70 | 14.35 |
| Enterprise Value (Cr.) | 28558.13 | 27786.54 | 23908.84 | 24195.45 | 21863.70 |
| EV / Net Operating Revenue (X) | 7.84 | 7.96 | 7.49 | 9.29 | 10.01 |
| EV / EBITDA (X) | 25.64 | 25.15 | 23.78 | 28.50 | 29.69 |
| MarketCap / Net Operating Revenue (X) | 8.02 | 8.09 | 7.47 | 9.19 | 9.95 |
| Retention Ratios (%) | 89.86 | 90.13 | 91.36 | 0.00 | 0.00 |
| Price / BV (X) | 6.18 | 6.63 | 6.60 | 7.25 | 7.70 |
| Price / Net Operating Revenue (X) | 8.02 | 8.09 | 7.47 | 9.19 | 9.95 |
| EarningsYield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Syngene International Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 12.35. This value is within the healthy range. It has decreased from 12.71 (Mar 24) to 12.35, marking a decrease of 0.36.
- For Diluted EPS (Rs.), as of Mar 25, the value is 12.34. This value is within the healthy range. It has decreased from 12.69 (Mar 24) to 12.34, marking a decrease of 0.35.
- For Cash EPS (Rs.), as of Mar 25, the value is 23.07. This value is within the healthy range. It has decreased from 23.28 (Mar 24) to 23.07, marking a decrease of 0.21.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 117.44. It has increased from 105.92 (Mar 24) to 117.44, marking an increase of 11.52.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 117.44. It has increased from 105.92 (Mar 24) to 117.44, marking an increase of 11.52.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 90.49. It has increased from 86.78 (Mar 24) to 90.49, marking an increase of 3.71.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 27.67. This value is within the healthy range. It has increased from 27.49 (Mar 24) to 27.67, marking an increase of 0.18.
- For PBIT / Share (Rs.), as of Mar 25, the value is 16.92. This value is within the healthy range. It has increased from 16.89 (Mar 24) to 16.92, marking an increase of 0.03.
- For PBT / Share (Rs.), as of Mar 25, the value is 16.40. This value is within the healthy range. It has increased from 15.44 (Mar 24) to 16.40, marking an increase of 0.96.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 12.33. This value is within the healthy range. It has decreased from 12.69 (Mar 24) to 12.33, marking a decrease of 0.36.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 12.33. This value is within the healthy range. It has decreased from 12.69 (Mar 24) to 12.33, marking a decrease of 0.36.
- For PBDIT Margin (%), as of Mar 25, the value is 30.57. This value is within the healthy range. It has decreased from 31.67 (Mar 24) to 30.57, marking a decrease of 1.10.
- For PBIT Margin (%), as of Mar 25, the value is 18.69. This value is within the healthy range. It has decreased from 19.46 (Mar 24) to 18.69, marking a decrease of 0.77.
- For PBT Margin (%), as of Mar 25, the value is 18.11. This value is within the healthy range. It has increased from 17.79 (Mar 24) to 18.11, marking an increase of 0.32.
- For Net Profit Margin (%), as of Mar 25, the value is 13.62. This value exceeds the healthy maximum of 10. It has decreased from 14.61 (Mar 24) to 13.62, marking a decrease of 0.99.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 13.62. This value is within the healthy range. It has decreased from 14.61 (Mar 24) to 13.62, marking a decrease of 0.99.
- For Return on Networth / Equity (%), as of Mar 25, the value is 10.49. This value is below the healthy minimum of 15. It has decreased from 11.97 (Mar 24) to 10.49, marking a decrease of 1.48.
- For Return on Capital Employeed (%), as of Mar 25, the value is 12.61. This value is within the healthy range. It has decreased from 13.56 (Mar 24) to 12.61, marking a decrease of 0.95.
- For Return On Assets (%), as of Mar 25, the value is 7.30. This value is within the healthy range. It has decreased from 8.29 (Mar 24) to 7.30, marking a decrease of 0.99.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.56. It has decreased from 0.58 (Mar 24) to 0.56, marking a decrease of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 1.64. This value is within the healthy range. It has decreased from 1.71 (Mar 24) to 1.64, marking a decrease of 0.07.
- For Quick Ratio (X), as of Mar 25, the value is 1.53. This value is within the healthy range. It has increased from 1.50 (Mar 24) to 1.53, marking an increase of 0.03.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.70. This value is within the healthy range. It has increased from 3.06 (Mar 24) to 4.70, marking an increase of 1.64.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 10.13. This value is below the healthy minimum of 20. It has increased from 9.86 (Mar 24) to 10.13, marking an increase of 0.27.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 5.41. This value is below the healthy minimum of 20. It has increased from 5.37 (Mar 24) to 5.41, marking an increase of 0.04.
- For Earning Retention Ratio (%), as of Mar 25, the value is 89.87. This value exceeds the healthy maximum of 70. It has decreased from 90.14 (Mar 24) to 89.87, marking a decrease of 0.27.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 94.59. This value exceeds the healthy maximum of 70. It has decreased from 94.63 (Mar 24) to 94.59, marking a decrease of 0.04.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 20.97. This value is within the healthy range. It has decreased from 23.41 (Mar 24) to 20.97, marking a decrease of 2.44.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 9.74. This value is within the healthy range. It has decreased from 12.04 (Mar 24) to 9.74, marking a decrease of 2.30.
- For Enterprise Value (Cr.), as of Mar 25, the value is 28,558.13. It has increased from 27,786.54 (Mar 24) to 28,558.13, marking an increase of 771.59.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 7.84. This value exceeds the healthy maximum of 3. It has decreased from 7.96 (Mar 24) to 7.84, marking a decrease of 0.12.
- For EV / EBITDA (X), as of Mar 25, the value is 25.64. This value exceeds the healthy maximum of 15. It has increased from 25.15 (Mar 24) to 25.64, marking an increase of 0.49.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 8.02. This value exceeds the healthy maximum of 3. It has decreased from 8.09 (Mar 24) to 8.02, marking a decrease of 0.07.
- For Retention Ratios (%), as of Mar 25, the value is 89.86. This value exceeds the healthy maximum of 70. It has decreased from 90.13 (Mar 24) to 89.86, marking a decrease of 0.27.
- For Price / BV (X), as of Mar 25, the value is 6.18. This value exceeds the healthy maximum of 3. It has decreased from 6.63 (Mar 24) to 6.18, marking a decrease of 0.45.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 8.02. This value exceeds the healthy maximum of 3. It has decreased from 8.09 (Mar 24) to 8.02, marking a decrease of 0.07.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Syngene International Ltd:
- Net Profit Margin: 13.62%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 12.61% (Industry Average ROCE: 48.42%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 10.49% (Industry Average ROE: 7.44%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 9.74
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.53
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 55.7 (Industry average Stock P/E: 42.75)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.02
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 13.62%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Biocon SEZ, Biocon Park, Bengaluru Karnataka 560099 | investor@syngeneintl.com http://www.syngeneintl.com |
| Management | |
|---|---|
| Name | Position Held |
| Ms. Kiran Mazumdar Shaw | Non Executive Chairman |
| Mr. Peter Bains | Managing Director & CEO |
| Prof. Catherine Rosenberg | Non Executive Director |
| Ms. Vinita Bali | Lead Independent Director |
| Mr. Nilanjan Roy | Independent Director |
| Dr. Kush Parmar | Independent Director |
| Ms. Sharmila Abhay Karve | Independent Director |
| Dr. Vijay Kuchroo | Independent Director |
| Mr. Manja Boerman | Independent Director |
FAQ
What is the intrinsic value of Syngene International Ltd?
Syngene International Ltd's intrinsic value (as of 13 December 2025) is 553.15 which is 14.51% lower the current market price of 647.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 26,070 Cr. market cap, FY2025-2026 high/low of 896/599, reserves of ₹4,332 Cr, and liabilities of 6,542 Cr.
What is the Market Cap of Syngene International Ltd?
The Market Cap of Syngene International Ltd is 26,070 Cr..
What is the current Stock Price of Syngene International Ltd as on 13 December 2025?
The current stock price of Syngene International Ltd as on 13 December 2025 is 647.
What is the High / Low of Syngene International Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Syngene International Ltd stocks is 896/599.
What is the Stock P/E of Syngene International Ltd?
The Stock P/E of Syngene International Ltd is 55.7.
What is the Book Value of Syngene International Ltd?
The Book Value of Syngene International Ltd is 118.
What is the Dividend Yield of Syngene International Ltd?
The Dividend Yield of Syngene International Ltd is 0.19 %.
What is the ROCE of Syngene International Ltd?
The ROCE of Syngene International Ltd is 13.5 %.
What is the ROE of Syngene International Ltd?
The ROE of Syngene International Ltd is 10.5 %.
What is the Face Value of Syngene International Ltd?
The Face Value of Syngene International Ltd is 10.0.